ModifiedCurativePolicy CHP-IP-2026-096

Acute Graft-Versus-Host Disease

Customize your policy alerts

Sign up for curative Policy CHP-IP-2026-096 alerts

Get alerted when Policy CHP-IP-2026-096 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This policy governs inpatient admission, level of care, continued stay, and discharge readiness for acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation, including steroid-refractory disease. It applies to Curative commercial PPO and EPO members in fully insured, level-funded, and self-funded plans; drug coverage is determined under applicable drug policies.

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

ModifiedCurativePolicy CHP-IP-2026-096

Acute Graft-Versus-Host Disease

Customize your policy alerts

Sign up for curative Policy CHP-IP-2026-096 alerts

Get alerted when Policy CHP-IP-2026-096 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerCurative

PolicyAcute Graft-Versus-Host Disease

Policy CodePolicy CHP-IP-2026-096

Change TypeModified

Effective DateN/A

Next Review DateN/A

Key ActionDocument at least one qualifying clinical severity finding and one hospital-level service for inpatient acute GVHD requests.

SourceLink

POLICY UPDATE CHANGES

The policy replaces the generic oncology template with MAGIC-based acute GVHD staging and admission criteria.

The policy defines steroid-refractory acute GVHD using progression after 3 days, no improvement after 7 days, or recurrence during corticosteroid taper.

Diagnosis codes that do not describe GVHD were removed from the policy.

10-21 daysCommon expected stay for grade III-IV acute GVHD

24 hoursConcurrent review interval

2 mg/kg/daySteroid-refractory definition dose

3 or 7 daysResponse assessment time points

24-72 hoursPost-discharge transplant follow-up

Eligible Acute GVHD Population

Allogeneic HSCT acute GVHD admission

Coverage applies to adults and children after allogeneic hematopoietic stem cell transplantation when inpatient acute GVHD criteria are met.

Post-allogeneic HSCT inpatient acute GVHD

Transplant context
- The patient is after allogeneic hematopoietic stem cell transplantation.
Medical necessity
- At least one qualifying acute GVHD clinical severity finding and at least one hospital-level service are present.

Inpatient Admission and Level-of-Care Criteria

Inpatient admission

Inpatient admission is medically necessary when BOTH a qualifying clinical severity finding and a hospital-level service are present.

Clinical severity finding
- Severity findings
  - MAGIC grade III or IV acute GVHD.
  - Lower GI stage 2 or higher; adult stool volume of at least 1000 mL/day; pediatric stool volume of at least 20 mL/kg/day; bloody stool; or severe abdominal pain.
  - Liver stage 2 or higher, with bilirubin above 3 mg/dL attributed to GVHD.
  - Grade II acute GVHD with volume depletion, electrolyte derangement, acute kidney injury, or inability to maintain oral intake.
  - Steroid-refractory or steroid-dependent acute GVHD requiring initiation of second-line therapy with inpatient monitoring.

Observation or outpatient instead of inpatient

Inpatient admission is not required when ANY of the following applies.

Outpatient or observation management

Grade I acute GVHD limited to skin, stage 1 to 2.
Topical therapy and outpatient follow-up are appropriate.
Grade II acute GVHD limited to skin or upper GI, with oral intake tolerated and stable laboratory values.
Oral or infusion-center corticosteroids with close outpatient follow-up are appropriate.
Chronic GVHD without an acute inpatient need.
Outpatient management is appropriate.

Intensive care unit

ICU care is appropriate when ANY of the following is present.

ICU level of care

Septic shock or hypotension requiring vasopressors, including neutropenic sepsis.
Acute respiratory failure requiring high-flow oxygen above 6 L/min with escalating needs, noninvasive positive pressure, or invasive ventilation.>6 L/min with escalating needs
Cytokine release syndrome ASTCT grade 3 or 4, or ICANS grade 3 or 4, including ICE score 0 to 2, seizures, motor weakness, or cerebral edema.
Tumor lysis syndrome with acute kidney injury requiring continuous renal replacement therapy, or life-threatening hyperkalemia or arrhythmia.

Step-down or intermediate care

Step-down or intermediate care is appropriate when ICU criteria are not met and ANY of the following is present.

CRS grade 2, or ICANS grade 1 to 2 requiring neurologic checks every 2 to 4 hours.
Laboratory tumor lysis syndrome or high tumor lysis syndrome risk requiring aggressive intravenous hydration, rasburicase, and electrolyte monitoring every 4 to 8 hours.
Febrile neutropenia with transient hypotension responsive to fluids, or other instability requiring more frequent nursing assessment than a ward provides.
High-volume diarrhea over 1500 mL/day with electrolyte instability requiring replacement and monitoring every 4 to 6 hours.>1500 mL/day

Medical-surgical level of care

An oncology medical-surgical bed is appropriate when ANY of the following applies and no higher-level criterion is met.

Medical-surgical unit

A hemodynamically stable patient is receiving inpatient chemotherapy, conditioning, cellular therapy monitoring, transfusion support, intravenous antimicrobials, or parenteral nutrition.
Neutropenic precautions with daily blood counts and transfusion thresholds are required, without instability.

Discharge readiness

Discharge is appropriate when ALL of the following are met.

GVHD has improved by at least one overall grade or organ stage, with stool volume and bilirubin trending down.
Oral intake is tolerated, or home parenteral nutrition is stable, with stable fluid and electrolyte balance.
The patient has transitioned to oral corticosteroids or oral second-line therapy with a taper plan.
No active infection requires intravenous therapy, and antimicrobial prophylaxis is in place.
Transplant clinic follow-up is arranged within 24 to 72 hours and caregiver support is available.

Continued-stay criteria

Continued inpatient stay is medically necessary when ANY of the following is documented.

Continued stay

Intravenous corticosteroids or other intravenous GVHD therapy are being provided and response has not yet been established.
Lower GI stage 2 or higher is present, or intravenous fluids, electrolytes, or parenteral nutrition are needed.
Infection requires intravenous therapy.

The following situations do not meet inpatient medical-necessity criteria: stable chronic GVHD without an acute inpatient need; grade I skin-only acute GVHD without other findings; staging workup, surveillance imaging, or elective biopsy without an acute inpatient need; and continued stay solely for outpatient scheduling, transportation, or lodging when the patient is medically stable. These services or circumstances are generally appropriate for outpatient management or discharge planning.

Admission solely for a regimen that is routinely and safely administered in an outpatient infusion center does not meet inpatient coverage criteria when there is no patient-specific risk requiring inpatient monitoring. The appropriate site of care is outpatient administration.

Low-risk febrile neutropenia is appropriate for outpatient management with oral antibiotics after an initial observation period when the patient has a MASCC score of 21 or higher, is hemodynamically stable, can take oral medication, and has reliable follow-up.

Applicable Codes and Clinical Thresholds

ICD-10-CM: GVHD and transplant complicationsICD-10

D89.810
D89.811
D89.812
D89.813
T86.00
T86.01
T86.02
T86.03
T86.09
T86.5

1–10 of 11

1/2

MS-DRG FY 2027 v44MS-DRG

814
815
816
840
841
842

Revenue codesRevenue

0250
0636
0300
0120

Adult lower GI stool volume

Stage 2 or higher thresholdAdult lower GI stool volume of >=1000 mL/day

Stage 2 range1000 to 1500 mL/day

Additional qualifying findingsBloody stool or severe abdominal pain also qualifies as a lower GI severity finding

Pediatric lower GI stool volume

Stage 2 or higher thresholdPediatric lower GI stool volume of >=20 mL/kg/day

Clinical significanceThis threshold qualifies as a lower GI stage 2 or higher severity finding for inpatient admission

Authorization, Documentation, and Review Requirements

Prior Authorization

Inpatient Acute GVHD Authorization

Obtain authorization for inpatient admission for acute GVHD. Medical necessity requires at least one qualifying clinical severity finding and at least one required hospital-level service.

Clinical severity: MAGIC grade III or IV; lower GI stage 2 or higher, bloody stool, or severe abdominal pain; liver stage 2 or higher with bilirubin above 3 mg/dL attributed to GVHD; grade II disease with volume depletion, electrolyte derangement, acute kidney injury, or inability to maintain oral intake; steroid-refractory or steroid-dependent disease requiring inpatient initiation of second-line therapy; or suspected infection in a patient receiving high-dose immunosuppression.
Hospital-level service: IV methylprednisolone with daily response assessment; IV fluids/electrolytes with measured stool output, bowel rest, or parenteral nutrition; endoscopy or skin/liver biopsy; IV antimicrobials or treatment of viral reactivation; or initiation of second-line therapy requiring inpatient monitoring for cytopenias or other complications.

Prior Authorization

Concurrent Continued-Stay Review

For each continued-stay period, document ongoing inpatient need. Concurrent review occurs every 24 hours, and continued authorization follows the supported criteria.

Diagnostic and Clinical Monitoring Documentation

Documentation Required

Complete diagnostic evaluation when indicated

When needed to confirm GVHD and exclude infection, perform endoscopy with biopsy or skin or liver biopsy and document the biopsy results and infection workup.

Documentation Required

Record daily staging and treatment response

Record daily MAGIC organ stages and the overall grade. Also document the corticosteroid dose and start date and assess response on days 3 and 7.

Acute GVHD Treatment and Monitoring

Inpatient acute GVHD treatment and monitoring

Ongoing IV GVHD therapyIntravenous corticosteroids or other intravenous GVHD therapy with response not yet established

Lower GI diseaseLower GI stage 2 or higher

Supportive therapyNeed for intravenous fluids, electrolytes, or parenteral nutrition

Infection treatmentInfection requiring intravenous therapy

Review intervalConcurrent review every 24 hours

GVHD Staging and Treatment Definitions

MAGIC overall grade

Grade ISkin stage 1 to 2 only

Grade IISkin stage 3 and/or upper GI and/or lower GI stage 1 and/or liver stage 1

Grade IIILiver stage 2 to 3 and/or lower GI stage 2 to 3

Grade IVSkin, liver, or lower GI stage 4

Steroid-refractory acute GVHD

Progression criterionProgression after 3 days of systemic corticosteroids

No-improvement criterionNo improvement after 7 days of systemic corticosteroids

Clinical Context

Acute graft-versus-host disease is a major cause of morbidity and non-relapse mortality after allogeneic hematopoietic stem cell transplantation. MAGIC criteria standardize assessment of skin, liver, upper gastrointestinal, and lower gastrointestinal involvement, with overall grades I through IV used to characterize severity. Grade II-IV disease is generally treated with systemic corticosteroids, while severe gastrointestinal or hepatic involvement may require hospitalization for intravenous therapy, fluid and electrolyte management, nutrition support, and infection surveillance.

Policy Summary

PayerCurative

PolicyAcute Graft-Versus-Host Disease

Policy CodePolicy CHP-IP-2026-096

Change TypeModified

Effective DateN/A

Next Review DateN/A

Key ActionDocument at least one qualifying clinical severity finding and one hospital-level service for inpatient acute GVHD requests.

SourceLink

On This Page

Suspected infection, including fever or sepsis, in a patient receiving high-dose immunosuppression for GVHD.

Hospital-level service

Services
- Intravenous methylprednisolone at 1 to 2 mg/kg/day with daily assessment of response.
- Intravenous fluids and electrolyte replacement with measured stool output, bowel rest, or parenteral nutrition.
- Endoscopy with biopsy or skin or liver biopsy to confirm GVHD and exclude infection.
- Intravenous antimicrobials or treatment of viral reactivation, such as CMV.
- Initiation of second-line therapy, such as ruxolitinib, when inpatient monitoring is needed for cytopenias or other complications.

Disseminated intravascular coagulation with active major bleeding, or leukostasis with respiratory or neurologic compromise.

Stage 4 GI GVHD with massive bleeding, ileus with perforation risk, or hemodynamic instability.

Additional qualifying findingsBloody stool or severe abdominal pain also qualifies as a lower GI severity finding

Liver involvement

Bilirubin thresholdBilirubin above 3 mg/dL

Liver stageLiver stage 2 or higher

AttributionThe liver involvement must be attributed to graft-versus-host disease

High-volume diarrhea

Daily stool-volume thresholdMore than 1500 mL/day

Associated concernElectrolyte instability requiring replacement

Monitoring expectationMonitoring every 4 to 6 hours

High-flow oxygen

Oxygen-flow thresholdHigh-flow oxygen above 6 L/min

Escalation criterionEscalating oxygen needs

Other ICU-level supportNoninvasive positive pressure or invasive ventilation

Febrile neutropenia red flag

Temperature thresholdFever of 38.0 C or higher

Absolute neutrophil count thresholdANC below 500/uL

Required responseObtain blood cultures and begin empiric broad-spectrum intravenous antibiotics within 1 hour; assess MASCC score and hemodynamics

IV corticosteroids or other IV GVHD therapy with response not yet established.
Lower GI stage 2 or higher, or ongoing need for IV fluids, electrolytes, or parenteral nutrition.
Infection requiring IV therapy.
Document extended-stay triggers when present, including steroid-refractory disease, stage 4 GI involvement, invasive infection, or parenteral-nutrition dependence. Expected length of stay is a planning benchmark, not a limit on covered days; authorized days are not retroactively denied.

Documentation Required

Diagnosis and Treatment Intent

Include the diagnosis and clinical context supporting the requested service, including pathology, disease status, and treatment intent.

Diagnosis with pathology results.
Current disease status.
Treatment intent.

Documentation Required

Treatment Regimen

Identify the treatment regimen and the planned inpatient components in the request and medical record.

Regimen name.
Cycle and day.
Planned inpatient components.

Documentation Required

Laboratory and Transfusion Monitoring

Provide daily monitoring information relevant to treatment safety and disease severity, including transfusion support and tumor-lysis surveillance when indicated.

Daily vital signs.
CBC with ANC.
Relevant chemistry, including potassium, phosphate, uric acid, creatinine, and LDH when tumor-lysis syndrome risk exists.
Transfusions given and the thresholds used.

Documentation Required

Infection Assessment

Document infection assessment and treatment throughout the admission, including the MASCC score when febrile neutropenia occurs.

Infection evaluation and workup.
Antimicrobial treatment.
MASCC score for febrile neutropenia.

Documentation Required

Standardized Severity Staging

Use standardized severity scales and provide daily GVHD organ assessments to support authorization and continued-stay review.

ASTCT grades for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
MAGIC staging and overall grade for acute GVHD.
Daily skin involvement by body-surface area, bilirubin, upper-GI symptoms, and measured stool volume.
Use WHO or CTCAE grading for mucositis when applicable.

Documentation Required

Discharge Planning

Document a practical discharge plan before discharge, including follow-up monitoring and the resources needed for safe outpatient care.

Laboratory follow-up plan.
Access to transfusions.
Caregiver support.

Documentation Required

Steroid Response

For corticosteroid-treated GVHD, record the start date and dose and assess response at the specified time points.

Corticosteroid start date.
Corticosteroid dose.
Response assessment on day 3.
Response assessment on day 7.

Documentation Required

Diagnostic Confirmation

Provide diagnostic confirmation supporting GVHD and exclusion of infectious causes.

Biopsy results, including endoscopic, skin, or liver biopsy results when performed.
Infection workup.

Documentation Required

Support the Requested Amount and Duration

Documentation must support the full requested service, including the amount, units, and duration.

Specify the requested quantity or amount.
Specify applicable units.
Specify the requested duration and support it with the clinical record.

Denial Risk

Grade I Skin-Only Disease

Admission for grade I acute GVHD limited to the skin is not medically necessary when there are no other qualifying findings. Topical therapy and outpatient follow-up are appropriate.

Grade I skin-only disease, stage 1 to 2, should generally be managed with topical therapy and outpatient follow-up.

Denial Risk

Stable Chronic GVHD

Stable chronic GVHD without an acute inpatient need should be managed in the outpatient setting.

Admission for stable chronic GVHD alone does not meet inpatient medical-necessity criteria.
Document the acute finding or hospital-level service if inpatient care is requested.

Denial Risk

Outpatient-Appropriate Regimen

Admission solely for a regimen that is routinely and safely administered in an outpatient infusion center does not meet criteria unless patient-specific risk requires inpatient monitoring.

Wrong site of care applies when no patient-specific inpatient monitoring need is documented.
Examples include standard regimens routinely administered in an outpatient infusion center.

Denial Risk

Convenience Days

A continued stay solely for scheduling, transportation, or lodging while the member is medically stable is a convenience stay and does not support continued inpatient days.

Refer for physician review and discharge planning.
Do not retroactively deny days that were already authorized.

Denial Risk

Elective Diagnostic Services

Staging workup, surveillance imaging, or elective biopsy without an acute inpatient need should be performed as outpatient services.

Document the acute inpatient need when diagnostic services are requested during an admission.

Prior Authorization

Requests Failing Criteria Require Physician Review

Requests that do not meet the stated criteria are referred for physician review and are not adversely determined by an automated system or non-physician reviewer.

Only a licensed physician of the same or similar specialty may issue an adverse determination.
The requesting provider must be offered a peer-to-peer discussion.
The reviewing physician must also meet applicable licensure, specialty, and medical-director requirements of the plan's situs state.

Denial Risk

Unsupported Excess Units or Duration

When the documentation supports only part of the requested quantity, units, or duration, approve the supported portion and refer only the unsupported excess for review.

Do not treat unsupported excess units or duration as a basis to adverse-determine the entire request.
The expected length of stay is a planning benchmark, not a limit on covered days.
The absence of a criterion addressing a service is not itself a basis for an adverse determination; physician review applies generally accepted standards of medical practice.

Corticosteroid dose2 mg/kg/day methylprednisolone equivalent

Taper criterionRecurrence during corticosteroid taper

MAGIC lower GI staging

Stage 1500 to 999 mL of stool per day

Stage 21000 to 1500 mL of stool per day

Stage 3More than 1500 mL of stool per day

Stage 4Severe abdominal pain with or without ileus or grossly bloody stool